Leqvio Cost in Missouri 2026: Prices, Insurance, Medicaid & Compounding

What Leqvio Costs Before Insurance

The current manufacturer support page states a Leqvio list price of $3,587.73 per dose for uninsured patients 2. List price is a benchmark, not the amount every patient pays.

The labeled schedule is one 284 mg injection initially, another at 3 months, and then one every 6 months 1. That means the labeled schedule normally involves three doses in the first 12 months and two doses in a later full maintenance year. Expressing this schedule as a flat monthly price can hide the loading doses and misstate a particular year’s drug acquisition cost.

Why the Final Missouri Bill Can Be Different

Leqvio is administered by a healthcare professional rather than self-injected at home 1. Novartis says it is primarily covered through the medical benefit, not the pharmacy benefit 2.

The patient’s responsibility can therefore depend on the medical-benefit pathway described by the manufacturer 2:

• whether the provider and administration site are in network;
• whether the claim uses buy-and-bill or a specialty distribution pathway;
• medical deductible and coinsurance;
• prior authorization or other medical-policy criteria;
• facility and administration charges;
• primary and secondary insurance; and
• whether financial assistance is valid for that coverage type.

A pharmacy coupon search alone may miss the relevant claim pathway. The most useful estimate is a written benefit verification for the exact provider and site of care.

A Reproducible Missouri Cost Check

1. Confirm the proposed site. Ask where the injection will be administered and whether that location is in network.
2. Ask which benefit applies. Verify whether the plan will process the drug under the medical or pharmacy benefit.
3. Request the exact coverage criteria. Obtain the current prior-authorization form or medical policy.
4. Get a benefit estimate. Ask for drug, administration, and facility amounts separately when possible.
5. Check secondary coverage. Medicare supplemental coverage and commercial secondary coverage can materially change the balance.
6. Screen assistance by insurance type. Commercial copay assistance and charitable patient assistance have different eligibility rules.
7. Recheck before each scheduled dose. Deductibles, sites, policies, and eligibility can change between injections.

This process produces a Missouri-specific estimate. A national list price or an uncited statewide “average” does not.

MO HealthNet Coverage in 2026

The MO HealthNet preferred drug list effective March 1, 2026 places Leqvio in the non-preferred column of the PCSK9 inhibitor class. It lists Praluent and a specified Repatha SureClick/syringe manufacturer entry as preferred, with other Repatha entries non-preferred 3.

The PDL itself says it is not all-inclusive and does not guarantee coverage 3. Non-preferred is not the same as “never covered.” It signals that the prescriber and plan should check the current authorization criteria and preferred alternatives.

The previous page said Missouri Medicaid excluded Leqvio for ASCVD and familial hypercholesterolemia but covered it for a type 2 diabetes indication. The current label does not list type 2 diabetes as a Leqvio indication, and the PDL does not support that claim. It has been removed 1 3.

Commercial Insurance and Prior Authorization

Commercial coverage is plan-specific. The manufacturer reports broad medical-benefit coverage, but manufacturer coverage statistics are not a guarantee for a Missouri plan or patient 2.

A request may need the diagnosis, current LDL-C, lipid-lowering treatment history, response or intolerance, and the reason a preferred product is not appropriate. The exact criteria must come from the member’s current plan. The earlier page assigned universal LDL thresholds, statin durations, and carrier approval patterns without the underlying policies; those claims have been removed.

Commercial Copay Assistance

Novartis states that eligible patients with private commercial insurance may pay as little as $0 through the Leqvio Copay Program. Per-treatment maximums, an annual cap, and other limitations apply. The offer is not valid for Medicare, Medicaid, TRICARE, VA, Department of Defense, or other federal or state programs 2.

“As little as $0” is not a guaranteed price. Eligibility, remaining program benefit, plan payment, site billing, and program terms determine the result.

Medicare and Patient Assistance

Because Leqvio is administered by a clinician, traditional Medicare may process an eligible treatment under Part B. The manufacturer says a person with traditional Medicare and qualifying supplemental coverage may owe as little as $0, while a person without supplemental coverage may be responsible for Part B coinsurance. Medicare Advantage cost sharing varies by plan 2.

Those are manufacturer summaries, not individual benefit determinations 2. The treating office should verify coverage with the plan before administration.

The Novartis Patient Assistance Foundation says it may provide certain Novartis medicines at no cost to eligible patients with limited or no prescription coverage who cannot afford them 6. Eligibility is not automatic, and the foundation may change its criteria.

Is Compounded Inclisiran a Cheaper Missouri Option?

No reliable evidence supports the earlier claim that licensed Missouri 503A pharmacies offer compounded inclisiran at a lower cash price. The page supplied no pharmacy, formulation, testing record, legal analysis, or price source.

FDA explains that compounded drugs are not FDA approved and that the agency does not verify their safety, effectiveness, or quality before marketing 5. A product described as “compounded inclisiran” should not be assumed equivalent to Leqvio, and a certificate of analysis alone would not establish clinical equivalence, sterility, stability, or lawful compounding.

There is no source-supported basis here to recommend compounded inclisiran as a cost substitute. FDA’s compounding overview explains why an unapproved compounded product cannot be presumed equivalent to the approved drug 5. A patient encountering such an offer should verify the product and legal status with the prescriber, dispensing pharmacy, Missouri Board of Pharmacy, and FDA rather than relying on the seller’s description.

What the Clinical Evidence Shows

Two phase 3 trials enrolled patients with elevated LDL cholesterol despite maximally tolerated statin therapy. Inclisiran reduced LDL-C by approximately 50% compared with placebo at day 510, with injection-site reactions more frequent in the inclisiran groups 4.

That trial supports LDL lowering. It should not be presented as a completed cardiovascular-outcomes trial. The current label’s claim is reduction of LDL-C as an adjunct to diet and exercise in its labeled populations 1.

The label updated in February 2026 includes adults with hypercholesterolemia and patients age 12 and older with heterozygous familial hypercholesterolemia, plus pediatric patients age 12 and older with homozygous familial hypercholesterolemia. The drug is contraindicated after a prior serious hypersensitivity reaction to inclisiran or its excipients. Common trial adverse reactions include injection-site reaction, arthralgia, and bronchitis 1.

Comparing Alternatives Without Inventing Prices

MO HealthNet’s preference for Praluent and certain Repatha products does not mean those drugs are clinically interchangeable for every patient or always cheaper under every plan 3.

A comparison should use the exact plan’s coverage for:

• Leqvio administration and site-of-care charges;
• self-injected PCSK9 monoclonal antibodies;
• statins and ezetimibe;
• bempedoic acid products; and
• any clinically appropriate alternative identified by the prescriber.

Different administration schedules, benefits, assistance rules, and outcome evidence make a single statewide cost table unreliable.